Matthew Caufield
Stock Analyst at H.C. Wainwright
(4.47)
# 1,168
Out of 5,133 analysts
360
Total ratings
42.6%
Success rate
10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Caufield
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Initiated Coverage: Buy | $76 | $57.41 | +32.38% | 1 | Nov 13, 2026 | |
| SVRA Savara | Initiated Coverage: Buy | $10 | $4.64 | +115.52% | 1 | Nov 12, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $8 → $14 | $3.98 | +251.76% | 38 | Nov 11, 2026 | |
| UPB Upstream Bio | Reiterated: Buy | $36 → $18 | $2.78 | +547.48% | 4 | Nov 11, 2026 | |
| ALDX Aldeyra Therapeutics | Reiterated: Hold | $2 | $0.6438 | +210.66% | 35 | Nov 10, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $56 | $15.33 | +265.30% | 24 | Nov 10, 2026 | |
| SRZN Surrozen | Reiterated: Buy | $54 | $31.61 | +70.83% | 12 | Nov 10, 2026 | |
| UTHR United Therapeutics | Initiated Coverage: Buy | $660 | $591.17 | +11.64% | 1 | Nov 9, 2026 | |
| ZBIO Zenas BioPharma | Reiterated: Buy | $44 | $28.01 | +57.09% | 21 | Nov 9, 2026 | |
| AKBA Akebia Therapeutics | Reiterated: Buy | $6 → $4 | $0.4742 | +743.53% | 14 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $7.52 | +192.55% | 19 | Nov 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $3.09 | +482.52% | 9 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $220 | $121.16 | +81.58% | 1 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $88 → $106 | $80.28 | +32.04% | 12 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $16 | $4.13 | +287.41% | 19 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $26 | $6.06 | +329.04% | 23 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $36 | $12.23 | +194.36% | 35 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $96 → $126 | $111.19 | +13.32% | 19 | Oct 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $8.79 | +36.52% | 14 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $6 | $0.9271 | +547.18% | 13 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.015 | n/a | 10 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.58 | n/a | 20 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 | - | n/a | 9 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $7.64 | n/a | 1 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $80.00 | n/a | 5 | Oct 21, 2022 |
Liquidia
Nov 13, 2026
Initiated Coverage: Buy
Price Target: $76
Current: $57.41
Upside: +32.38%
Savara
Nov 12, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.64
Upside: +115.52%
Opus Genetics
Nov 11, 2026
Reiterated: Buy
Price Target: $8 → $14
Current: $3.98
Upside: +251.76%
Upstream Bio
Nov 11, 2026
Reiterated: Buy
Price Target: $36 → $18
Current: $2.78
Upside: +547.48%
Aldeyra Therapeutics
Nov 10, 2026
Reiterated: Hold
Price Target: $2
Current: $0.6438
Upside: +210.66%
Mineralys Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $56
Current: $15.33
Upside: +265.30%
Surrozen
Nov 10, 2026
Reiterated: Buy
Price Target: $54
Current: $31.61
Upside: +70.83%
United Therapeutics
Nov 9, 2026
Initiated Coverage: Buy
Price Target: $660
Current: $591.17
Upside: +11.64%
Zenas BioPharma
Nov 9, 2026
Reiterated: Buy
Price Target: $44
Current: $28.01
Upside: +57.09%
Akebia Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $6 → $4
Current: $0.4742
Upside: +743.53%
Nov 6, 2026
Reiterated: Buy
Price Target: $22
Current: $7.52
Upside: +192.55%
Nov 4, 2026
Reiterated: Buy
Price Target: $18
Current: $3.09
Upside: +482.52%
Nov 4, 2026
Initiated Coverage: Buy
Price Target: $220
Current: $121.16
Upside: +81.58%
Nov 4, 2026
Reiterated: Buy
Price Target: $88 → $106
Current: $80.28
Upside: +32.04%
Oct 30, 2026
Reiterated: Buy
Price Target: $38 → $16
Current: $4.13
Upside: +287.41%
Oct 30, 2026
Reiterated: Buy
Price Target: $26
Current: $6.06
Upside: +329.04%
Oct 22, 2026
Reiterated: Buy
Price Target: $36
Current: $12.23
Upside: +194.36%
Oct 12, 2026
Reiterated: Buy
Price Target: $96 → $126
Current: $111.19
Upside: +13.32%
Sep 21, 2026
Reiterated: Buy
Price Target: $12
Current: $8.79
Upside: +36.52%
Aug 4, 2026
Reiterated: Buy
Price Target: $8 → $6
Current: $0.9271
Upside: +547.18%
Aug 22, 2025
Rated: Hold
Price Target: n/a
Current: $0.015
Upside: n/a
May 27, 2025
Rated: Hold
Price Target: n/a
Current: $2.58
Upside: n/a
May 19, 2025
Reiterated: Hold
Price Target: $9
Current: -
Upside: n/a
Oct 29, 2024
Reiterated: Buy
Price Target: $39
Current: $7.64
Upside: n/a
Oct 21, 2022
Rated: Hold
Price Target: n/a
Current: $80.00
Upside: n/a